Opna Bio
Pre-Approval PRO BETA 🟡
Slowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 8/22/2024
5
Total Trials
0
Phase 3
2
Phase 2
1
Recruiting
31
Score
Pipeline by Phase
Phase 3
Phase 2
2
Phase 1
5
Therapeutic Focus
Relapsed Multiple Myeloma Refractory Multiple Myeloma Metastatic Castration-resistant Prostate Cancer Gynecologic Neoplasms Epithelial Ovarian Cancer
Clinical Trials (5)
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Started: 8/22/2024
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Started: 9/21/2020
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Started: 8/11/2020
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Started: 3/19/2019
Drug Candidates
OPN-6602 Dexamethasone PLX2853 20 mg Olaparib Abiraterone acetate Prednisone PLX2853 40 mg PLX2853 80 mg PLX2853 Carboplatin
Activity Status:
Slowing
Last Trial Started: 8/22/2024
Last Trial Ended: 5/24/2022
Trials (12 months): 0
Completed Trials: 2
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.